Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:SBOT

Stellar Biotechnologies (SBOT) Stock Price, News & Analysis

Stellar Biotechnologies logo

About Stellar Biotechnologies Stock (NASDAQ:SBOT)

Advanced Chart

Key Stats

Today's Range
$6.42
$6.69
50-Day Range
$4.44
$298,098.00
52-Week Range
$0.75
$3.25
Volume
3.16 million shs
Average Volume
2.95 million shs
Market Capitalization
$34.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Stellar Biotechnologies, Inc., a biotechnology company, engages in the aquaculture, research and development, manufacture, and commercialization of keyhole limpet hemocyanin (KLH) protein in Europe, North America, and Asia. The company offers KLH, an immune-stimulating protein used in the production of various immunotherapies; and as a carrier molecule or finished injectable product in the immunodiagnostic market. It provides its KLH protein under the Stellar KLH brand. The company's products include Stellar KLH protein in various grades, formulations, custom configurations, and fill finishes for drug development and research applications, as well as KLH-based in vitro diagnostic kits for research and preclinical use. Its customers and partners comprise biotechnology and pharmaceutical companies, academic institutions, clinical research organizations, and research centers. Stellar Biotechnologies, Inc. is based in Port Hueneme, California.

Receive SBOT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Stellar Biotechnologies and its competitors with MarketBeat's FREE daily newsletter.

SBOT Stock News Headlines

Now I look stupid. Real stupid...
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Stellar Bancorp, Inc. Declares Quarterly Dividend
See More Headlines

SBOT Stock Analysis - Frequently Asked Questions

Stellar Biotechnologies Inc (NASDAQ:SBOT) issued its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported ($0.31) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.05. The biotechnology company had revenue of $0.12 million for the quarter, compared to analysts' expectations of $0.11 million. Stellar Biotechnologies had a negative net margin of 1,782.64% and a negative trailing twelve-month return on equity of 51.12%.

Shares of Stellar Biotechnologies reverse split before market open on Monday, May 7th 2018. The 1-7 reverse split was announced on Friday, April 27th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 4th 2018. An investor that had 100 shares of stock prior to the reverse split would have 14 shares after the split.

Based on aggregate information from My MarketBeat watchlists, some other companies that Stellar Biotechnologies investors own include NightHawk Biosciences (NHWK), NexGen Energy (NXE), XOMA (XOMA), Anavex Life Sciences (AVXL), EyePoint Pharmaceuticals (EYPT), OPKO Health (OPK) and Rigel Pharmaceuticals (RIGL).

Company Calendar

Last Earnings
5/08/2019
Today
4/26/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SBOT
Fax
N/A
Employees
25
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-5,030,000.00
Net Margins
-1,782.64%
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$210,000.00
Price / Cash Flow
N/A
Book Value
$2.12 per share
Price / Book
3.07

Miscellaneous

Free Float
N/A
Market Cap
$34.65 million
Optionable
Not Optionable
Beta
N/A
7 Stocks to Buy And Hold Forever Cover

Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

This page (NASDAQ:SBOT) was last updated on 4/26/2025 by MarketBeat.com Staff
From Our Partners